Now showing items 1-20 of 4635

    • Mendelian randomisation study of smoking exposure in relation to breast cancer risk. 

      Park, HA; Neumeyer, S; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Ahearn, TU; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Augustinsson, A; Baten, A; Beane Freeman, LE; Becher, H; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Brucker, SY; Burwinkel, B; Campa, D; Canzian, F; Castelao, JE; Chanock, SJ; Chenevix-Trench, G; Clarke, CL; NBCS Collaborators; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Daly, MB; Devilee, P; Dörk, T; Dos-Santos-Silva, I; Dwek, M; Eccles, DM; Eliassen, AH; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Flyger, H; Fritschi, L; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Giles, GG; Glendon, G; Goldberg, MS; Goldgar, DE; González-Neira, A; Grip, M; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Han, S; Harkness, EF; Hart, SN; He, W; Heemskerk-Gerritsen, BAM; Hopper, JL; Hunter, DJ; ABCTB Investigators; kConFab Investigators; Jager, A; Jakubowska, A; John, EM; Jung, A; Kaaks, R; Kapoor, PM; Keeman, R; Khusnutdinova, E; Kitahara, CM; Koppert, LB; Koutros, S; Kristensen, VN; Kurian, AW; Lacey, J; Lambrechts, D; Le Marchand, L; Lo, W-Y; Lubiński, J; Mannermaa, A; Manoochehri, M; Margolin, S; Martinez, ME; Mavroudis, D; Meindl, A; Menon, U; Milne, RL; Muranen, TA; Nevanlinna, H; Newman, WG; Nordestgaard, BG; Offit, K; Olshan, AF; Olsson, H; Park-Simon, T-W; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Presneau, N; Radice, P; Rennert, G; Rennert, HS; Romero, A; Saloustros, E; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Schoemaker, MJ; Schwentner, L; Scott, C; Shah, M; Shu, X-O; Simard, J; Smeets, A; Southey, MC; Spinelli, JJ; Stevens, V; Swerdlow, AJ; Tamimi, RM; Tapper, WJ; Taylor, JA; Terry, MB; Tomlinson, I; Troester, MA; Truong, T; Vachon, CM; van Veen, EM; Vijai, J; Wang, S; Wendt, C; Winqvist, R; Wolk, A; Ziogas, A; Dunning, AM; Pharoah, PDP; Easton, DF; Zheng, W; Kraft, P; Chang-Claude, J
      <h4>Background</h4>Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, it is still equivocal whether smoking is causally related to breast cancer ...
    • Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. 

      Carvalho, DM; Richardson, PJ; Olaciregui, N; Stankunaite, R; Lavarino, C; Molinari, V; Corley, EA; Smith, DP; Ruddle, R; Donovan, A; Pal, A; Raynaud, FI; Temelso, S; Mackay, A; Overington, JP; Phelan, A; Sheppard, D; Mackinnon, A; Zebian, B; Al-Sarraj, S; Merve, A; Pryce, J; Grill, J; Hubank, M; Cruz, O; Morales La Madrid, A; Mueller, S; Carcaboso, AM; Carceller, F; Jones, C (2021-09-22)
      Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), however there are no ACVR1 inhibitors licensed for the disease. Using an Artificial Intelligence-based platform ...
    • The evolving management of epithelioid sarcoma. 

      Alves, A; Constantinidou, A; Thway, K; Fisher, C; Huang, P; Jones, RL (2021-07-18)
    • ADP-ribosyltransferases, an update on function and nomenclature. 

      Lüscher, B; Ahel, I; Altmeyer, M; Ashworth, A; Bai, P; Chang, P; Cohen, M; Corda, D; Dantzer, F; Daugherty, MD; Dawson, TM; Dawson, VL; Deindl, S; Fehr, AR; Feijs, KLH; Filippov, DV; Gagné, J-P; Grimaldi, G; Guettler, S; Hoch, NC; Hottiger, MO; Korn, P; Kraus, WL; Ladurner, A; Lehtiö, L; Leung, AKL; Lord, CJ; Mangerich, A; Matic, I; Matthews, J; Moldovan, G-L; Moss, J; Natoli, G; Nielsen, ML; Niepel, M; Nolte, F; Pascal, J; Paschal, BM; Pawłowski, K; Poirier, GG; Smith, S; Timinszky, G; Wang, Z-Q; Yélamos, J; Yu, X; Zaja, R; Ziegler, M (2021-07-29)
      ADP-ribosylation, a modification of proteins, nucleic acids, and metabolites, confers broad functions, including roles in stress responses elicited, for example, by DNA damage and viral infection and is involved in intra- ...
    • A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. 

      Sarker, D; Dawson, NA; Aparicio, AM; Dorff, TB; Pantuck, AJ; Vaishampayan, UN; Henson, L; Vasist, L; Roy-Ghanta, S; Gorczyca, M; York, W; Ganji, G; Tolson, J; de Bono, JS (2021-07-19)
      <h4>Purpose</h4>In patients with metastatic castration-resistant prostate cancer (mCRPC), resistance to androgen receptor (AR) targeted therapies, such as enzalutamide, remains an issue. Inactivation of inhibitory phosphatase ...
    • Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service. 

      Lidington, E; Darlington, AS; Vlooswijk, C; Beardsworth, S; McCaffrey, S; Tang, S; Stallard, K; Younger, E; Edwards, P; Ali, AI; Nandhabalan, M; Din, A; Starling, N; Larkin, J; Stanway, S; Nobbenhuis, M; Banerjee, S; Szucs, Z; Gonzalez, M; Sirohi, B; Husson, O; van der Graaf, WTA
      <h4>Aims</h4>Adolescents and young adults aged 15-39 years with cancer face unique medical, practical and psychosocial issues. In the UK, principal treatment centres and programmes have been designed to care for teenage ...
    • Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysis. 

      Tomasik, B; Bieńkowski, M; Braun, M; Popat, S; Dziadziuszko, R
      <h4>Background</h4>Immune checkpoint inhibitors (ICIs) are standard of care in advanced non-small cell lung cancer (NSCLC), however their status in patients with poor performance status (PS) is poorly defined. We aimed to ...
    • Identification of 22 susceptibility loci associated with testicular germ cell tumors. 

      Pluta, J; Pyle, LC; Nead, KT; Wilf, R; Li, M; Mitra, N; Weathers, B; D'Andrea, K; Almstrup, K; Anson-Cartwright, L; Benitez, J; Brown, CD; Chanock, S; Chen, C; Cortessis, VK; Ferlin, A; Foresta, C; Gamulin, M; Gietema, JA; Grasso, C; Greene, MH; Grotmol, T; Hamilton, RJ; Haugen, TB; Hauser, R; Hildebrandt, MAT; Johnson, ME; Karlsson, R; Kiemeney, LA; Lessel, D; Lothe, RA; Loud, JT; Loveday, C; Martin-Gimeno, P; Meijer, C; Nsengimana, J; Quinn, DI; Rafnar, T; Ramdas, S; Richiardi, L; Skotheim, RI; Stefansson, K; Turnbull, C; Vaughn, DJ; Wiklund, F; Wu, X; Yang, D; Zheng, T; Wells, AD; Grant, SFA; Rajpert-De Meyts, E; Schwartz, SM; Bishop, DT; McGlynn, KA; Kanetsky, PA; Nathanson, KL; Testicular Cancer Consortium (2021-07-23)
      Testicular germ cell tumors (TGCT) are the most common tumor in young white men and have a high heritability. In this study, the international Testicular Cancer Consortium assemble 10,156 and 179,683 men with and without ...
    • The molecular pathology of infant gliomas 

      Clarke, M (2021-04-30)
      Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumours. I have collected 241 cases ...
    • Intratumor morphologic and transcriptomic heterogeneity in <sup>V600E</sup>BRAF-mutated metastatic colorectal adenocarcinomas. 

      Angerilli, V; Fontana, E; Lonardi, S; Sbaraglia, M; Borelli, B; Munari, G; Salmaso, R; Guzzardo, V; Spolverato, G; Pucciarelli, S; Pilati, P; Hahne, JC; Bergamo, F; Zagonel, V; Dei Tos, AP; Sadanandam, A; Loupakis, F; Valeri, N; Fassan, M
      Background Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity ...
    • Targeting androgen receptor splicing in lethal prostate cancer 

      Paschalis, A (2021-04-30)
      Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
    • Genetics of high risk myeloma 

      Shah, V (2021-03-31)
      Despite significant progress in therapy in the last two decades, the outlook for multiple myeloma (MM) patients is still poor as the disease remains incurable and only 33% of patients survive for up to 10 years after ...
    • JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer. 

      Ruiz, EJ; Lan, L; Diefenbacher, ME; Riising, EM; Da Costa, C; Chakraborty, A; Hoeck, JD; Spencer-Dene, B; Kelly, G; David, J-P; Nye, E; Downward, J; Behrens, A (2021-07-08)
      The AP-1 transcription factor c-Jun is required for Ras-driven tumorigenesis in many tissues and is considered as a classical proto-oncogene. To determine the requirement for c-Jun in a mouse model of K-RasG12D-induced ...
    • Deficient adaptation to centrosome duplication defects in neural progenitors causes microcephaly and subcortical heterotopias. 

      González-Martínez, J; Cwetsch, AW; Martínez-Alonso, D; López-Sainz, LR; Almagro, J; Melati, A; Gómez, J; Pérez-Martínez, M; Megías, D; Boskovic, J; Gilabert-Juan, J; Graña-Castro, O; Pierani, A; Behrens, A; Ortega, S; Malumbres, M (2021-08-23)
      Congenital microcephaly (MCPH) is a neurodevelopmental disease associated with mutations in genes encoding proteins involved in centrosomal and chromosomal dynamics during mitosis. Detailed MCPH pathogenesis at the cellular ...
    • Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. 

      Alexander, JL; Ibraheim, H; Sheth, B; Little, J; Khan, MS; Richards, C; Hunter, N; Chauhan, D; Ratnakumaran, R; McHugh, K; Pinato, DJ; Nathan, P; Choy, J; Crusz, SM; Furness, A; Turajlic, S; Pickering, L; Larkin, J; Teare, JP; Papa, S; Speight, A; Sharma, A; Powell, N
      Introduction Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically ...
    • Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. 

      Switzer, B; Haanen, J; Lorigan, PC; Puzanov, I; Turajlic, S
      The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review ...
    • Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour. 

      Jay, APM; Aldiwani, M; O'Callaghan, ME; Pearce, AK; Huddart, RA; Mayer, E; Reid, AH; Nicol, DL
      Background Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr.Objective To review features of ...
    • Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. 

      Chamberlain, F; Benson, C; Thway, K; Huang, P; Jones, RL; Gennatas, S (2021-04-21)
      Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ...
    • Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. 

      Popat, S; Brustugun, OT; Cadranel, J; Felip, E; Garassino, MC; Griesinger, F; Helland, Å; Hochmair, M; Pérol, M; Bent-Ennakhil, N; Kruhl, C; Novello, S
      Background The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitor-naïve ALK-positive advanced NSCLC and in patients previously treated with crizotinib. A phase II trial showed that ...